Hi Mike,

Yes, the 6 week test will be the first. I will be going next Saturday.

A.L. is the resident troll. He keeps us on our toes.

We need to be ready in case Gilead sends a professional, scumbag troll. A.L. is lightweight….he’s playing devil’s advocate.

We all need to go easy on the cowboy I agree that the post was a little strange, but he lives in Texas. I live in NJ, but my company headquarters is in FL. These “right to work” states seem to feature “right to die” health insurance regulations. Like my insurance carrier BCBS in FL who only treat “transplant waiting list patients”. I mean really, what kind of evil shit is that? Probably the same in Texas…my point being he may have a lot of problems.

Yes, this is great info!

If you can get your insurance to approve Harvoni or Sovaldi, Gilead offers a co-pay coupon through their ‘Support Path’ program so that your co-pay is only $5 a month

Google Gilead Support Path for info.

This is great news! As long as the government doesn’t go too far (I have faith, even cutting the price in half would be a major achievement in USA )

Pharmasset, the company Gilead bought that created the drug was going to charge $35K for 12 weeks of Harvoni. While still expensive, in the US I think most insurance carriers would pay for it for most patients.

But Twinvir (generic Harvoni) is under $1500 for 12 weeks, shipped via DHL to your door

If you are in USA, email my friend at curehcvnow@gmail.com for details

Congratulations Splitdog!

Hope your next test comes back UND!

My post earlier about India trying to enter into RCEP was just trying to shed some light as to why this action has been taken.

Hopefully I am wrong, and shipments will continue. I tried to find an article I read about Gilead’s strategy in India, but don’t seem to be able to find it. Gilead’s strategy in allowing Indian companies to produce the meds was to allow the truly poor of the world to access meds, but also to be able to keep control of exports to “rich” countries like USA. Gilead requires an Indian doctor to issue an RX for a reason; apparently they are able to get information about the country of origin of the buyer, so that they can see if a reseller is exporting where they should not be and then contact the manufacturer to have them cut off from supply. I’m sure bulk exports to the 91 countries Gilead deems poor will continue.

This direct intervention by the Indian customs is an escalation in strategy, or perhaps based on the RCEP agreement, as the countries in RCEP overlap TPP countries, with some in both agreements. So the requirements may be similar concerning trade.

Gilead will accept medical tourism to India; it will still be possible to travel to India and get an RX and meds there. Obviously, that is much more expensive and bothersome.